ArticleObesity (Silver Spring, Md.)2025
Development and validation of an eating behavior patient-reported outcome measure in people living with obesity or overweight.
Article in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.Diabetes, obesity & metabolism · 2026Trial
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).Diabetes, obesity & metabolism · 2026Trial
- Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.Diabetes, obesity & metabolism · 2026Article
- Psychometric Validation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity or Overweight.Advances in therapy · 2026Article
- Development and validation of an eating behavior patient-reported outcome measure in people living with obesity or overweight.Obesity (Silver Spring, Md.) · 2025Article
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).Obesity (Silver Spring, Md.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThe objective of this study was to develop a measure of eating behaviors in adults living with obesity or overweight.
methodsBased on concept-elicitation (n = 53) and cognitive-debriefing (n = 15) studies, a draft eating behavior patient-reported outcome (EB PRO) measure was developed. Its psychometric properties were established using data from a 46-week clinical trial of an investigational antiobesity medication (n = 387).
resultsThe final EB PRO comprised 12 items across two domains (i.e., "Desire to Eat" and "Capacity to Resist"; 6 items each) and a Total Eating Behavior score (0-48; higher scores worse). The EB PRO demonstrated good test-retest reliability (intraclass correlation coefficients > 0.7). Confirmatory factor analysis showed a comparative fit index of 0.98 with good internal consistency (Cronbach α > 0.7). The EB PRO generally exhibited moderate-to-large correlations with the Patient Global Impression of Severity questionnaire and Three-Factor Eating Questionnaire and weaker correlation with the 36-Item Short-Form Health Survey version 2 Physical Functioning scale. All EB PRO scores improved from baseline to week 46 (p < 0.0001), demonstrating sensitivity to change with therapy. Clinically meaningful thresholds were defined as eight- and four-point changes in Total Eating Behavior and domain scores, respectively.
conclusionsThe EB PRO measure is a promising tool for assessing eating behaviors in people with obesity or overweight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.